EFL021 - Metabolic Effects of a Dual GIP and GLP-1 RA
Join host Chase Hendrickson, MD, from Vanderbilt Unviersity Medical Center, as he discusses a recent article in The Journal of Clinical Endocrinology & Metabolism with Ashok Balasubramanyam, MD, from…
Read the full articleYou might also wanna read
Tirzepatide in the treatment of metabolic dysfunction-associated steatotic liver disease in adults: A review of randomized clinical trials
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease worldwide and is stro
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
GLP1RA and tirzepatide, crucial in T2DM and obesity management, show poor real-world persistence with high discontinuation. What’s driving t
Study identifies patients with obesity most likely to benefit from GLP-1-based treatment
Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic study offers a p
Study Identifies Patients with Obesity Most Likely to Benefit From GLP-1-Based Treatment
Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic study offers a p
Tirzepatide
Your Daily, No-Needle Weight Loss Solution Targets both GLP-1 and GIP pathways Supports weight loss and satiety Conveniently place tablet un
twc.health·17d agoTirzepatide
Your Daily, No-Needle Weight Loss Solution Targets both GLP-1 and GIP pathways Supports weight loss and satiety Conveniently place tablet un
twc.health·17d agoPhenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us
Explore the real-world impact: A study analyzed 17,267 T2D adults on GLP-1 RAs, revealing downstream health effects with electronic health r
Comments
Sign in to join the conversation.
No comments yet. Be the first.